Biofrontera Inc. (BFRI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BFRI POWR Grades
- BFRI scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.97% of US stocks.
- The strongest trend for BFRI is in Growth, which has been heading up over the past 78 days.
- BFRI ranks lowest in Stability; there it ranks in the 16th percentile.
BFRI Stock Summary
- BIOFRONTERA INC's market capitalization of $17,354,351 is ahead of just 7.5% of US-listed equities.
- BIOFRONTERA INC's stock had its IPO on October 29, 2021, making it an older stock than only 1.41% of US equities in our set.
- BIOFRONTERA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -80.79%, greater than the shareholder yield of only 7.32% of stocks in our set.
- Stocks that are quantitatively similar to BFRI, based on their financial statements, market capitalization, and price volatility, are HURC, LGL, NVFY, ROCK, and AIR.
- To check out BIOFRONTERA INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001858685.
BFRI Valuation Summary
- BFRI's EV/EBIT ratio is -3.6; this is 154.96% lower than that of the median Healthcare stock.
- BFRI's price/sales ratio has moved down 1.6 over the prior 17 months.
Below are key valuation metrics over time for BFRI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BFRI | 2023-03-17 | 0.6 | 0.7 | -27.2 | -3.6 |
| BFRI | 2023-03-16 | 0.6 | 0.7 | -26.3 | -2.2 |
| BFRI | 2023-03-15 | 0.6 | 0.7 | -26.1 | -1.9 |
| BFRI | 2023-03-14 | 0.6 | 0.7 | -26.1 | -1.9 |
| BFRI | 2023-03-13 | 0.5 | 0.6 | -23.9 | 1.5 |
| BFRI | 2023-03-10 | 0.5 | 0.7 | -1.2 | 1.1 |
BFRI Stock Price Chart Interactive Chart >
BFRI Price/Volume Stats
| Current price | $0.64 | 52-week high | $6.12 |
| Prev. close | $0.62 | 52-week low | $0.55 |
| Day low | $0.64 | Volume | 4,265 |
| Day high | $0.64 | Avg. volume | 121,707 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $1.17 | Market Cap | 17.09M |
Biofrontera Inc. (BFRI) Company Bio
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Latest BFRI News From Around the Web
Below are the latest news stories about BIOFRONTERA INC that investors may wish to consider to help them evaluate BFRI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning! |
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual MeetingBiofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology (AAD) Annual Meeting taking place March 17-21, 2023 in New Orleans, LA. |
Biofrontera Inc. (NASDAQ:BFRI) Analysts Just Slashed Next Year's EstimatesThe latest analyst coverage could presage a bad day for Biofrontera Inc. ( NASDAQ:BFRI ), with the analysts making... |
Biofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call TranscriptBiofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Greetings and welcome to the Biofrontera, Inc. Fourth quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the form of presentation. I will now turn the conference over to your host, […] |
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsBiofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31, 2022. |
BFRI Price Returns
| 1-mo | N/A |
| 3-mo | -31.91% |
| 6-mo | -30.66% |
| 1-year | -78.81% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -30.18% |
| 2022 | -87.81% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...